We are thrilled to announce a significant milestone for PL BioScience! In a recent press release, we reveal that we have successfully closed a €7.8 million Series A financing round. This Series A funding marks a pivotal moment in our company’s growth journey. This substantial infusion
The companies agree to a worldwide Human Platelet Lysate (HPL) Patent License and Assignment Agreement regarding Human Platelet Lysate (HPL) cell culture supplements, including redirection of HPL customers from Macopharma to PL BioScience. PL BioScience GmbH, a German life science company specializing in the production and
“Cell culture with Human Platelet Lysate – Recycled blood for new medicine" Regenerative medicine is developing rapidly. And cell cultivation plays a crucial role for the development, especially in stem cell therapy. Therefore, the demand for safe cell culture media is increasing – as a basis
“Cell cultivation: Anticoagulant-free Human Platelet Lysate” About LABO Journal LABO, a German journal for laboratory technology, introduced our new product ELAREM™ Perform-FD PLUS in the article: “Cell cultivation: Anticoagulant-free Human Platelet Lysate”. The LABO journal is specialized in scientific news, inventions and updates concerning the daily lab
“We are driven by the fact that our Human Platelet Lysate accelerates the developments in the treatment of life-threatening diseases." Dr. Hatim Hemeda, CEO About GIT The German GIT Labor-Fachzeitschrift (Lab Journal) just published a company portrait about PL BioScience. The article gives insights into our vision, the
Nutrient media for the development of regenerative therapies In the latest interview at bionity.com, our CEO Dr. Hatim Hemeda talked about the history and background idea of PL BioScience to develop nutrient media for the development of regenerative therapies. As a young life science company we develop, produce
New Press Release: Sustainable Cell Culture Medium A new press release "Recently at the bench: cell culture with Human Platelet Lysate - Sustainable Cell Culture Media" in the German Laborjournal edition from December 2021 was published. Our CEO Hatim Hemeda had the opportunity to write a guest
New press release on our Human Platelet Lysate. Read the article (in German) online via: https://www.labo.de/zell-und-mikrobiologie/tierfreies-naehrmedium.htm The LABO journal is specialized in scientific news, inventions and updates concerning the daily lab routine. So, it addresses analytics and diagnostics, new lab techniques, chemistry, food, environmental influences as well as
'Accelerating research and discovery' – Human Platelet Lysate in North America 'Accelerating research and discovery'. The mission of the team at Captivate Bio perfectly fits our mission: Providing one solution for all development stages – Human Platelet Lysate. From the beginning, we saw strong synergies between our companies.
PL BioScience starts up complementary workspace at Medace The Aachen-based biotechnology company PL BioScience was founded in 2015 as a spin-off of the RWTH Aachen University, with the idea of delivering animal component-free cell culture supplements. PL BioScience has developed an advanced nutrient solution for
PL BioScience raises € 3.7 mln from Born2Grow, Brightlands Venture Partners, TechVision Fund I and more The capital will be used to expand R&D, increase sales capacity and scale up in-house production PL BioScience produces a human-based nutrient medium for growing cells, as replacement for animal-derived
Introducing our new human Platelet Lysate brand name: ELAREM™ As a university spin-off, we started manufacturing our human Platelet Lysates (hPL) back in 2015, as ‘PL Solution’ products. For more than five years, you may know our human Platelet Lysates under this name. It is time
Read in the press article from the "Aachener Zeitung" why human Platelet Lysate is still unusual but morally inoffensive PL BioScience produces human Platelet Lysate (hPL) as a cell culture supplement. This is still unusual because using the controversial Fetal Bovine Serum (FBS) for cell culture
The TechVision Fonds brings in new capital in PL BioScience We are proud to announce that with the support of SilverSky LifeSciences we successfully managed to convince the TechVision Fonds to invest in our start-up business. The TechVision Fonds, managed by the S-UBG group, supports innovative start-up
Cell Culture innovation without the need of animal serum Our innovative cell culture media pave the way to a new standard of cell cultivation, without the need of animal serum. Human Platelet Lysate is highly efficient It is highly efficient, resource-preserving and replaces procedures associated with animal suffering:
PL BioScience is mentioned in the local newspaper ‘Aachener Zeitung’ one more time. Prior to the award ceremony on 6 June 2019, PL BioScience is presented in the recent press article as one of the five finalists. Our whole team is delighted about the appreciation and innovative strength
The five finalists of the AC² Innovation Award 2019 for the Aachen region have just presented their technologies to the jury. Beforehand, the AGIT (Aachen Society for Innovation and Technology Transfer), the chambers and universities selected numerous local companies with innovative strength. We are very pleased to
